Efficacy and Safety of Angiogenesis Inhibitors Combined with Poly ADP Ribose Polymerase Inhibitors in the Maintenance Treatment of Advanced Ovarian Cancer: a Meta-analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Dec 3

PMID 39624625

Authors

Renming Huang

Feng Ji

Leyi Huang

Yueying Qin

Zhiyu Liang

Miaoyan Huang

Chunyan Li

Jian Ban

Affiliations

Soon will be listed here.

Abstract

Introduction: This meta-analysis was performed to evaluate the efficacy and safety of angiogenesis inhibitors (Ais) combined with poly ADP ribose polymerase inhibitors (PARPi) in the maintenance treatment of advanced ovarian cancer (OC).

Materials And Methods: A systematic search was conducted in four databases (Pubmed, Embase, Web of Science, and Cochrane) for articles published from the inception of the databases until January 15, 2024. The focus of the search was on articles investigating the combination of Ais with PARPi in the maintenance treatment of ovarian cancer. Meta-analyses were conducted to assess the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and the risk of Grade ≥ 3 adverse events (Grade≥ 3 AEs).

Results: Totally nine studies were included for meta-analysis. The overall pooled ORR of Ais combined with PARPi was 57% (95% CI, 35% to 77%). Subgroup analyses showed that the ORR for patients with platinum-resistant recurrent ovarian cancer, platinum-sensitive recurrent ovarian cancer and newly diagnosed advanced ovarian cancer were 30% (95% CI, 12% to 52%), 70% (95% CI, 61% to 78%) and 59% (95% CI, 55% to 63%), respectively. The median PFS was 5.8 months (95% CI, 5.3 to 7.1), 12.4 months (95% CI, 10.6 to 13.2) and 22.4 months (95% CI, 21.5 to 24.2), respectively. The median OS was 15.5 months (95% CI, 12.3 to 24.8), 40.8 months (95% CI, 33.4 to 45.2) and 56.3 months (95% CI, 49.0 to 62.0), respectively. The rate Grade≥ 3 TRAEs rate was found to be 0.22 (95% CI, 0.13 to 0.33).

Conclusions: Our results confirmed that PARPi plus Ais was a feasible and safe option for the maintenance treatment of advanced ovarian cancer. The combination therapy should be recommended as the first-line maintenance treatment for patients with advanced ovarian cancer. PARPi plus Ais yielded more favorable oncological prognosis for patients with platinum-sensitive recurrent ovarian cancer, compared to patients with platinum-resistant recurrent ovarian cancer.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024543590, identifier CRD42024543590.

References

Colombo N, Tomao F, Benedetti Panici P, Nicoletto M, Tognon G, Bologna A . Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer. Gynecol Oncol. 2022; 164(3):505-513. DOI: 10.1016/j.ygyno.2022.01.015. View

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

Zardavas D, Tryfonidis K, Goulioti T, Piccart M . Targeted adjuvant therapy in breast cancer. Expert Rev Anticancer Ther. 2016; 16(12):1263-1275. DOI: 10.1080/14737140.2016.1247698. View

Javed Ansari M, Bokov D, Markov A, Turki Jalil A, Shalaby M, Suksatan W . Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Commun Signal. 2022; 20(1):49. PMC: 8991477. DOI: 10.1186/s12964-022-00838-y. View

Liu J, Brady M, Matulonis U, Miller A, Kohn E, Swisher E . Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022; 40(19):2138-2147. PMC: 9242406. DOI: 10.1200/JCO.21.02011. View

Banares R, Albillos A, Rincon D, Alonso S, Gonzalez M, Ruiz-Del-Arbol L . Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology. 2002; 35(3):609-15. DOI: 10.1053/jhep.2002.31354. View

Kim Y, Joung J, Park E, Kim J, Lee J, Lim J . Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045. Int J Cancer. 2023; 153(12):2032-2044. DOI: 10.1002/ijc.34696. View

Liu N, Zhou Y, Lee J . IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021; 21(1):111. PMC: 8168323. DOI: 10.1186/s12874-021-01308-8. View

Cumpston M, Li T, Page M, Chandler J, Welch V, Higgins J . Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019; 10:ED000142. PMC: 10284251. DOI: 10.1002/14651858.ED000142. View

10.

McCann K . Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer. Curr Opin Obstet Gynecol. 2017; 30(1):7-16. DOI: 10.1097/GCO.0000000000000428. View

11.

Bindra R, Crosby M, Glazer P . Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 2007; 26(2):249-60. DOI: 10.1007/s10555-007-9061-3. View

12.

OMalley D, Krivak T, Kabil N, Munley J, Moore K . PARP Inhibitors in Ovarian Cancer: A Review. Target Oncol. 2023; 18(4):471-503. PMC: 10344972. DOI: 10.1007/s11523-023-00970-w. View

13.

Bindra R, Schaffer P, Meng A, Woo J, Maseide K, Roth M . Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol. 2004; 24(19):8504-18. PMC: 516750. DOI: 10.1128/MCB.24.19.8504-8518.2004. View

14.

Jiang X, Li X, Li W, Bai H, Zhang Z . PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med. 2019; 23(4):2303-2313. PMC: 6433712. DOI: 10.1111/jcmm.14133. View

15.

Mirza M, Avall Lundqvist E, Birrer M, Christensen R, Nyvang G, Malander S . Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019; 20(10):1409-1419. DOI: 10.1016/S1470-2045(19)30515-7. View

16.

Chan N, Pires I, Bencokova Z, Coackley C, Luoto K, Bhogal N . Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res. 2010; 70(20):8045-54. PMC: 2978949. DOI: 10.1158/0008-5472.CAN-10-2352. View

17.

Heckman C, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Yla-Herttuala S . The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008; 68(12):4754-62. DOI: 10.1158/0008-5472.CAN-07-5809. View

18.

Tentori L, Lacal P, Muzi A, Dorio A, Leonetti C, Scarsella M . Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer. 2007; 43(14):2124-33. DOI: 10.1016/j.ejca.2007.07.010. View

19.

Liu G, Feng Y, Li J, Deng T, Yin A, Yan L . A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study. EClinicalMedicine. 2022; 54:101767. PMC: 9793276. DOI: 10.1016/j.eclinm.2022.101767. View

20.

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View